Latest news with #FUJIFILMHealthcareAmericasCorporation
Business Wire
08-05-2025
- Health
- Business Wire
Fujifilm's EN-840T Double Balloon Enteroscopy Scope Wins 2025 MedTech Breakthrough Award
LEXINGTON, Mass.--(BUSINESS WIRE)-- FUJIFILM Healthcare Americas Corporation, a leading provider of endoscopic imaging and endosurgical solutions, announced that its EN-840T Double Balloon Enteroscopy (DBE) Scope, an endoscopic imaging technology that enables access to the entire small intestine for diagnosis and therapeutic intervention, has been selected as the winner of the 'Best New Endoscopy Technology Solution' award in the 9th annual MedTech Breakthrough Awards program. MedTech Breakthrough is an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital health and medical technology market. The EN-840T DBE scope represents a major update to Fujifilm's pioneering Double Balloon Enteroscopy technology. The EN-840T DBE scope features several compelling features, including its ability to allow for blood or mucus to be aspirated while a therapeutic device is inserted, enabling quicker hemostasis. The scope also provides a dedicated forward water jet channel for irrigation and enables clinicians to quickly clear debris like blood on the mucous membranes for clearer visualization of the bowel wall. 'As a company with a history of 'firsts' in the endoscopy field, we're honored to be recognized by MedTech Breakthrough for our ergonomically designed EN-840T DBE scope,' said Tai Fujita, general manager of endoscopy and vice president, FUJIFILM Healthcare Americas Corporation. 'Approximately 2.39 million Americans have Inflammatory Bowel Disease (IBD), which includes Crohn's disease and ulcerative colitis. Left undiagnosed and untreated, these diseases can lead to serious complications. We're proud to offer clinicians a tool that will help them access difficult to reach pathways within the digestive tract, enabling them to more effectively diagnose and treat a wide array of small intestine diseases, gastrointestinal bleeding, and removal of small bowel polyps.' A CMOS (Complementary Metal-Oxide-Semiconductor) image sensor in the EN-840T DBE scope ensures vivid, HD, high-quality images, providing speed and clarity for diagnosis. The scope also leverages LED multi-light technology along with Fujifilm's Linked Color Imaging (LCI)® and Blue Light Imaging (BLI) modes to provide endoscopists with enhanced visualization and enable optimal detection during small bowel procedures. The EN-840T DBE scope also provides adaptive bending and advanced force transmission technology for improved access and scope maneuverability in challenging anatomy. 'Fujifilm is both setting and elevating the gold standard in small bowel access for diagnosis and treatment. In gastrointestinal (GI) endoscopy, access is often challenged by difficult to reach pathways within the digestive tract,' said Steve Johansson, managing director, MedTech Breakthrough. 'With the EN-840T, endoscopists and GI physicians now have access to a new, novel tool to help combat this anatomical challenge and enable optimal detection during small bowel procedures, empowering them to truly push the envelope for deep small bowel diagnostics and therapeutics.' The MedTech Breakthrough Awards program celebrates excellence and innovation in the health and medical technology industry, recognizing the companies, products, and solutions driving meaningful progress and improving patient care. This year's program attracted more than 4,500 nominations from over 18 different countries throughout the world. To learn more about Fujifilm's EN-840T DBE scope, click here. About Fujifilm FUJIFILM Healthcare Americas Corporation is a comprehensive healthcare company that has an extensive range of technology and expertise in the detection, diagnosis, and treatment of diseases. Fujifilm's innovative portfolio includes solutions spanning diagnostic imaging, enterprise imaging, endoscopic imaging, surgical imaging, and in-vitro diagnostics. The Non-Destructive Testing group delivers radiography solutions to ensure high accuracy inspection of transportation infrastructure, and assets within aerospace, and oil and gas industries. The company is headquartered in Lexington, Massachusetts. For more information on healthcare offerings, please visit and for NDT portfolio, please visit FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of 'giving our world more smiles,' we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen. For more information, please visit:
Associated Press
12-02-2025
- Business
- Associated Press
Fujifilm and EndoSim Partner to Expand Access to Advanced Endoscopy Training
Lexington, MA., Feb. 12, 2025 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Americas Corporation, a leading provider of endoscopy and endosurgery solutions, has partnered with EndoSim, a pioneer in evidence-based endoscopic simulation, to expand access to EndoGel,* a training model that simulates human tissue to help endoscopists practice endoscopic submucosal dissection (ESD) and peroral endoscopic myotomy (POEM) procedures. Through this partnership, Fujifilm will transfer its exclusive U.S. distributorship of EndoGel to EndoSim, expanding access of this critical training tool to the full market. Fujifilm identified a training gap in the U.S. market for ESD and POEM procedures, which are cutting-edge and lifesaving minimally invasive endoscopic surgical procedure more widely in Asian healthcare markets. This gap stemmed from a lack of practice material (aside from living tissue, animal tissue, and cadaver tissue) to train on highly technically complex procedure methods, leading the company to explore other options and ultimately bring EndoGel to the U.S. market in July 2022. EndoGel addresses this problem by simulating the texture of human tissue involved in ESD and POEM procedures, providing clinicians with a life-like simulation experience. With this unique and innovative training model, endoscopy professionals can benefit from the ability to: • practice marking and injecting, • perform circumferential incisions, • perform submucosal dissection, myotomy and clipping. 'As part of Fujifilm's commitment to endoscopy innovation, we are dedicated to bridging the educational divide in advanced procedures in the United States,' says Tai Fujita, general manager of endoscopy, FUJIFILM Healthcare Americas Corporation. 'By partnering with EndoSim to expand distributorship of EndoGel, together we are not just filling a training gap; we are setting new standards for education in endoscopic procedures that ultimately lead to better patient care.' 'Endosim is excited to partner with Fujifilm on the distribution of EndoGel in the United States. We appreciate the synergistic partnership with Fujifilm to improve access to endoscopic training,' said Kai Matthes, M.D., Ph.D., founder & chief executive officer, EndoSim LLC. 'We believe that EndoGel will be a valuable addition to our products and services in interventional endoscopy simulation. The ease of use of EndoGel will provide seamless access to practice novel, third space endoscopic procedures in the clinical setting when access to a hands-on lab is not available. EndoGel can be used in the endoscopy unit without the requirement to have dedicated endoscopic equipment for procedural training.' To learn more about EndoGel, visit or contact [email protected]. To learn more about Fujifilm, visit *EndoGel is owned and manufactured by Sunarrow Limited, Tokyo, Japan. EndoGel is a joint development between Sunarrow and the Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Japan. About Fujifilm FUJIFILM Healthcare Americas Corporation is a comprehensive healthcare company that has an extensive range of technology and expertise in the detection, diagnosis, and treatment of diseases. Fujifilm's innovative portfolio includes solutions spanning diagnostic imaging, enterprise imaging, endoscopic imaging, surgical imaging, and in-vitro diagnostics. The company is headquartered in Lexington, Massachusetts. For more information, please visit FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of 'giving our world more smiles,' we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen (29 billion USD at an exchange rate of 140 JPY/USD). For more information, please visit: click here. About EndoSim Endosim is the market leader in endoscopic simulation and training in the United States and Europe. The Endosim Training Center and manufacturing plant are located in Bolton, Massachusetts. An additional Endosim Training Center in Schwabach, Germany, is servicing the European market. Endosim is partnering with many medical device companies and societies such as the American College of Gastroenterology, the American Society for Gastrointestinal Endoscopy, the American College of Surgeons, the Society of American Gastrointestinal Endoscopic Surgeons, and the European Society for Gastrointestinal Endoscopy.
